Curanex Pharmaceuticals Inc’s (NASDAQ:CURX) Lock-Up Period Set To End on February 23rd

Curanex Pharmaceuticals’ (NASDAQ:CURX) lock-up period is set to end on Monday, February 23rd. Curanex Pharmaceuticals had issued 3,750,000 shares in its IPO on August 26th. The total size of the offering was $15,000,000 based on an initial share price of $4.00. After the end of the company’s lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Wall Street Analyst Weigh In

Several brokerages have weighed in on CURX. Weiss Ratings reissued a “sell (e-)” rating on shares of Curanex Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen downgraded Curanex Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Curanex Pharmaceuticals presently has an average rating of “Sell”.

Curanex Pharmaceuticals Price Performance

Shares of NASDAQ:CURX opened at $0.29 on Monday. Curanex Pharmaceuticals has a 12 month low of $0.26 and a 12 month high of $9.18. The company has a market cap of $8.12 million and a P/E ratio of -5.73. The firm’s 50-day moving average price is $0.36.

Curanex Pharmaceuticals (NASDAQ:CURX) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.04) earnings per share (EPS) for the quarter.

Institutional Trading of Curanex Pharmaceuticals

A hedge fund recently bought a new stake in Curanex Pharmaceuticals stock. Citadel Advisors LLC bought a new stake in shares of Curanex Pharmaceuticals Inc (NASDAQ:CURX) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 64,067 shares of the company’s stock, valued at approximately $46,000.

About Curanex Pharmaceuticals

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.